Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

San Diego Biotechnology Network
San Diego Biotechnology Network
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate
Loading
/

Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in the US in coming years. The company Thursday announced it had inked a deal [?]